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Received 5 February 2008; received in revised form 25 July 2008; accepted 26 July 2008Abstract Generating surrogate insulin-producing cells from embryonic stem cells (ESCs) through in vitro replication of
successive steps during pancreatic development has been challenging . Here we describe a novel reproducible protocol to
establish homogeneous and scalable insulin-producing cell lines from mouse (m) ESCs via differentiation of the previously
described lineage-restricted clonal mESC-derived E-RoSH cells. Unlike their parental mESCs, E-RoSH cells expressed high levels
of mesodermal and endodermal genes. Nutrient depletion in the presence of nicotinamide inhibited proliferation of E-RoSH
cells and induced differentiation into heterogeneous cultures comprising vascular-like structures that produced detectable
levels of insulin and C-peptide in an equimolar ratio. Limiting dilution of these cultures resulted in the isolation of eight
independent insulin-producing cell lines in five experiments. All these lines were cloned and shown to be amenable to repeated
cycles of freeze and thaw and to replicate for months with a doubling time of 3–4 days. Under such conditions, the cultured cells
exhibited genomic, structural, biochemical, and pharmacological properties of pancreatic β cells, including storage of an
equimolar ratio of insulin and C-peptide in granules and release of the contents of these organelles through a glucose-sensitive
machinery. After transplantation, these cells reversed hyperglycemia in streptozotocin-treated SCID mice and did not form
teratomas.
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Diabetes is a severe metabolic syndrome of global epidemic
proportions that involves the loss of insulin-producing β cells
(Mathis et al., 2001; Porte and Kahn, 2001). Restoring insulin-
producing β-cell mass by pancreatic islet transplantation is
effective in treating diabetes (Shapiro et al., 2000), but is
limited by a shortage of donor organs. Unfortunately,
alternative sources of insulin-producing cells, e.g., embryo-
nic stem cells (ESCs) or adult progenitor cell pools, have not
generated sufficiently high yields of homogeneous insulin-
producing cells (Rosenberg, 1995; Ramiya et al., 2000;
Bonner-Weir et al., 2000; Soria et al., 2000; Assady et al.,
2001; Zulewski et al., 2001; Lumelsky et al., 2001; Hori et
al., 2002; Li et al., 2003; Houard et al., 2003; Seaberg et al.,
2004; Fujikawa et al., 2005; Shi et al., 2005; D’Amour et al.,
2006; Fellous et al., 2007). Consequently, it has not been
possible to test rigorously the therapeutic potential of these
cells, with regard to the production of high levels of properly
processed insulin, the release of the hormone in a glucose-
induced and regulated manner, and the lack of teratoma-
forming potential (Colman, 2004; Halban, 2004; Bonner-Weir
and Weir, 2005).
Most strategies to generate insulin-producing cells from
ESCs generally start with the spontaneous formation of
embryoid bodies (EBs), consisting of cells from all three germ
layers (Schroeder et al., 2006b). Although the culture
conditions used for the formation of EBs bear little
resemblance to the embryonic microenvironment, the
temporal and spatial representation of major embryonic
cell types in EBs somehow recapitulate some of the early
events in embryo development (Doetschman et al., 1985;
Doetschman et al., 1993). To increase the yield of the few
insulin-producing cells found in EBs (Soria, 2001), most
approaches have so far relied on the provision of specific
components of the extracellular matrix, signal molecules,
transcription factors, and/or growth factors to mimic
essential steps in pancreas development and to enhance
endodermal differentiation and selection of insulin-
producing cells (Assady et al., 2001; Lumelsky et al., 2001;
Leon-Quinto et al., 2004; Fujikawa et al., 2005; Shi et al.,
2005; D’Amour et al., 2006; Schroeder et al., 2006a). The
fidelity of these in vitro differentiation strategies to the
embryonic development of pancreatic β cells is often
monitored by the expression of genes associated with each
developmental stage. There is currently a substantial knowl-
edge base of the temporal, spatial, and quantitative
interactions of a large number of signaling molecules and
transcription factors, including Pdx-1, HNFs, neurogenin 3,
NeuroD1, Pax4, and Nkx6.1, that are important in regulating
proper pancreatic organogenesis and β-cell differentiation
and maintaining β-cell phenotype (Edlund, 2002; Herrera et
al., 2002; Chakrabarti and Mirmira, 2003; Hebrok, 2003;
D’Amour et al., 2006). Despite these efforts, differentiating
ESC into secretory-competent insulin-producing cells remains
inefficient and yields cell preparations with poorly charac-
terized stimulus-secretion coupling pathways and carries a
significant risk of teratoma formation (Rosenberg, 1995;
Ramiya et al., 2000; Bonner-Weir et al., 2000; Soria et al.,
2000; Assady et al., 2001; Zulewski et al., 2001; Lumelsky et
al., 2001; Hori et al., 2002; Li et al., 2003; Houard et al.,
2003; Colman, 2004; Seaberg et al., 2004; Halban, 2004;Fujikawa et al., 2005; Shi et al., 2005; Bonner-Weir and Weir,
2005; D’Amour et al., 2006).
In this report, we describe the development of an
innovative and reproducible approach to generating highly
scalable insulin-producing cell lines from mESCs. This
approach also starts with the formation of EBs, from which
we first established clones of lineage-restricted E-RoSH
progenitor cell lines through the selection of CD9-positive
and SSEA-1-negative cells (Lian et al., 2006). E-RoSH cells do
not express pluripotency-associated genes such as Oct3/4,
Sox2, and Nanog, but express high levels of endoderm- and
mesoderm-associated genes and reduced levels of ecto-
derm-associated genes. Consequently, they cannot form
teratomas and are better poised to differentiate into
mesoderm- and endoderm-derived cells. We have previously
demonstrated that these cells differentiate readily into
mesodermal tissues such as endothelial cells in vitro and in
vivo (Lian et al., 2006; Que et al., 2007). Here, we report
that these cells can also differentiate into endodermal cells,
such as insulin-producing cells, under serum-depleted
culture conditions in the presence of nicotinamide. In
these cultures, we were able to segregate insulin-producing
cells from the other cell types by limiting dilution and to
reproducibly establish several cell lines that produce
sufficient amounts of insulin to correct the hyperglycemia
of diabetic mice in vivo.
Results
E-RoSH cells differ from ESC and differentiate
predominantly into endodermal and mesodermal
lineages
We have previously postulated that as a result of their high
expression of mesoderm- and endoderm-associated genes, E-
RoSH cell lines are better poised than their parental ESCs to
differentiate into mesoderm and endoderm cells (Lian et al.,
2006). Here we compared the change in gene expression
pattern of E14 mESCs and ERoSH2.1 cells, an E14-derived E-
RoSH line, when they were induced to undergo spontaneous
differentiation by culturing single cells in suspension (105
cells per 6-cm plate). After 48 h, ESCs formed tightly packed
EBs (Fig. 1A), while E-RoSH cells formed hollow bodies (Fig.
1B). This difference in morphogenesis was paralleled by a
notable difference in the gene expression profile of the
cultures. Most of the mesoderm- and endoderm-associated
genes analyzed, such as Runx1 (Runt-related transcription
factor 1), Kit (Kit oncogene), Tek (tyrosine kinase, endothe-
lial), Gata4 (GATA-binding protein 4), Afp (α-fetoprotein),
Foxa2 (Forkhead box A2), Fabp2 (fatty acid-binding protein
2), Hnf4a (hepatocyte nuclear factor 4α), and Sox17 (SRY-
box 17), were expressed at N10-fold higher levels in
differentiating E-RoSH than in differentiating ESC cells (Fig.
1C). There were exceptions, namely, Cer1 (Cerberus 1
homolog) andMixl1 (Mix1 homeobox-like 1) (Fig. 1D). Several
genes whose expression is associated with endocrine tissues,
including pancreatic β cells, were also highly expressed in
the differentiating ESCs (Fig. 1D). As many of these genes,
such as Hesx1 (homeobox gene expressed in ES cells), Pcsk1
(proprotein convertase subtilisin/kexin type 1), Pax6
(paired-box gene 6), Neurog3 (neurogenin 3), and Ptf1a
Figure 1 E-RoSH cells and mESCs show distinct differentiation potentials. E-RoSH cells and mESCs undergo spontaneous
differentiation when grown in suspension culture. (A) Typical ESC-derived EBs at day 7. (B) Typical E-RoSH cell-derived EBs at day 7 of
culture. (C, D) TaqMan PCR analysis of RNA extracted after 0, 2, 3, and 7 days of culture showing the relative expression of mesodermal
and endodermal genes (C) and ectodermal (D) genes in mESCs (open bars) and E-RoSH2.1 cells (gray bars). The transcript level of each
gene at day 0 in ESCs was designated as 1 and all other transcript levels were normalized to this value. The relative transcript levels are
represented on a logarithmic scale. Values are means±SD for two experiments.
43ESC-derived insulin-producing cell lines(pancreas-specific transcription factor 1a), are also
expressed in early ectodermal tissues, we postulated that
the expression of these genes in differentiating ESCs
reflected the development of early ectodermal tissue in
the differentiating ESCs. Together, these observations sug-
gest that unlike mESCs, which differentiate into tissues of all
three germ layers, E-RoSH cells are developmentally poised
for differentiation into endodermal and mesodermal cells.E-RoSH cells can differentiate into insulin-producing
cells
We next determined whether E-RoSH cells could be induced
to differentiate into insulin-producing cells. Using a protocol
as summarized in Fig. 2A, we initiated differentiation of E-
RoSH cells by serum starvation. We have previously shown
that serum starvation inhibits PI3K/mTOR signaling in E-RoSH
cells and induces apoptosis and initiates endothelial differ-
entiation (Que et al., 2007). Within 24–48 h of serum dep-
rivation, E-RoSH2.1 cells differentiated to form capillary-likestructures (Fig. 2B) with a concomitant upregulation of
endothelial markers (Que et al., 2007). However, insulin or C-
peptide was never detectable in these cultures unless the
medium was supplemented with 10 mM nicotinamide (Fig.
2C). Nicotinamide is thought to be important in the
replication and differentiation of pancreatic β cells (Sandler
et al., 1989; Otonkoski et al., 1993) and consistently induced
the production of detectable levels of insulin and C-peptide
proteins in an equimolar ratio (Fig. 2C). Deprivation of serum
caused the death of all cells within 4 days. On the other
hand, replenishing the serum-starved cultures with fresh
medium containing10% FCS on day 3 led to a gradual loss of
insulin and C-peptide production (Fig. 2C) and a return to an
E-RoSH cell-like phenotype, possibly due to the overwhelm-
ing growth of the rapidly proliferating E-RoSH cells over the
slow-growing insulin-producing cells.
To facilitate the isolation of the insulin-producing cells,
we used gleevec, an inhibitor of c-Kit (Kit oncogene), PDGFR
(platelet-derived growth factor receptor), and c-Abl (c-Abl
oncogene 1, receptor tyrosine kinase) (Druker, 2004), to
inhibit the proliferation of E-RoSH cells, which were
Figure 2 E-RoSH cells differentiate to insulin-producing ERoSHK cell lines. (A) A schematic diagram of differentiation of mESCs into
insulin-producing cell lines. (B) After 24 h culture in the absence of serum, E-RoSH2.1 cells formed vascular-like structures. (C) Insulin
and C-peptide levels in three E-RoSH2.1 cell cultures were measured before induction of differentiation (left), after induction of
differentiation by serum starvation for 72 h, followed by a 48-h exposure to 10 mM nicotinamide (middle), and 4 days after
differentiation, when culture medium was replaced with INS medium containing10% FCS (right). Values are means±SEM of at least
three independent experiments. (D) Effects of 5 μM gleevec on the viability of undifferentiated E-RoSH 2.1 cells. At 0, 24, 48, and 72 h,
cells were stained with both CFDA and PI. Values are mean (±SEM) numbers of CFDA-positive and PI-negative cells as determined by
flow cytometry in three experiments, expressed relative to that at 0 h. (E–G) Phase-contrast views of parental E-RoSH2 cells (E) and
derived ERoSHK-1 (F) and ERoSHK-4 cells (G) after 10 passages.
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2006), and to enhance β-cell survival (Hagerkvist et al.,
2007). We found that 5 μM gleevec inhibited the proliferation
of E-RoSH2.1 cells (Fig. 2D). Limiting dilution of two gleevec-
treated cultures resulted in the cloning of two cell lines,
ERoSHK-1 and ERoSHK-2, that were morphologically similar
to each other but distinct from the parental E-RoSH2.1 cells
(Figs. 2E and 2F). In subsequent experiments, we were able
to clone six additional insulin-producing cell lines by serum
starvation, nicotinamide treatment, and then limited dilu-
tion in three independent experiments, without the use of
gleevec (Fig. 2A).
In our hands, differentiation of E-RoSH cells into hetero-
geneous insulin-producing cultures was a highly reproducible
5- to 10-day process. The main difficulty was in isolating
sufficient insulin-producing cells for cloning without anycontaminating parental E-RoSH cells. The large differential
in the doubling time between ERoSHK (doubling time
∼3days) and E-RoSH cells (doubling time 12–15 h) was such
that when the selective pressure of serum starvation and
nicotinamide treatment against E-RoSH cells was removed,
residual E-RoSH cells quickly outgrew any insulin-producing
cells. To illustrate, a heterogeneous culture of ERoSHK and E-
RoSH cells at a ratio of 99:1 would have an inverse ratio of
1:99 in about 6 days. In performing limiting dilution of the
heterogeneous differentiated E-RoSH cultures to establish
ERoSHK cell lines, we determined empirically that the
optimal protocol was to expose a starting population of
4×108 E-RoSH cells to repeated cycles of serum starvation
and nicotinamide treatment, thus reducing the cell number
to about 1000 cells and possibly also increasing the yield of
insulin-producing cells.
45ESC-derived insulin-producing cell linesAltogether, we isolated eight insulin-producing cell lines,
referred to as ERoSHK-1 to -8, in five independent experi-
ments. All these lines share a similar epithelial morphology
(Figs. 2F and 2G).
ERoSHK cell lines show characteristics of primary
β cells
ERoSHK cells and parental ERoSH2.1 cells were distinctly
different from each other. Global gene expression levels in
ERoSHK cells and parental ERoSH2.1 cells were poorly
correlated (r2=0.22; Fig. 3A). Also, ERoSHK cells had a
population doubling time of∼3 days, which was considerably
slower than the 12- to 15-h doubling time of E-RoSH cells
(Lian et al., 2006). The total cellular insulin content of the
eight ERoSHK lines ranged from 35 to 570 pmol (or 0.2
to 3.4 μg)/106 cells, with an equimolar concentration of
C-peptide (Fig. 3B).
We characterized the in vitro and in vivo properties of
the ERoSHK-4 and ERoSHK-6 lines at passages 10–22.
Immunostaining showed that N90% of ERoSHK-4 and
ERoSHK-6 cells contained detectable levels of insulin (Fig.
3C, middle), while only about 10% of them contained
glucagon (Fig. 3C, right). We also observed a fairly constantFigure 3 ERoSHK cells produce insulin and C-peptide. (A) Genome-w
RoSH cell line using Illumina Sentrix Mouse Ref-8 Expression Bead C
different ERoSHK clonal cell lines that were derived in five indepen
(Left) H&E staining shows the epithelial phenotype of ERoSHK-4 c
staining detected (middle) insulin and (right) glucagon in ERoSHK-4 c
cells over 27 passages. Values are means±SEM of at least three expelevel of insulin and C-peptide in ERoSHK-4 cells at various
passages for 27 passages (Fig. 3D), suggesting that insulin
biosynthesis in these cells was not affected by long-term
passaging or repeated cycles of freeze–thaw. Reverse
transcriptase-polymerase chain reaction (RT-PCR) analysis
indicated that ERoSHK-4 (Fig. 4A) and ERoSHK-6 cells (data
not shown) did not express somatostatin and pancreatic
polypeptide, but expressed most of the pancreatic genes
found in adult mouse islets, including those coding for
proinsulin-1 and- 2 (Ins1 and Ins2), Glut2 (Slc2a2), glucoki-
nase (Gck), prohormone convertases 1/3 (Pcsk), two subunits
of KATP channels (Kir 6.2, Sur-1), insulin receptor substrate
2 (IRS2), glucagon (Gcg); low levels of islet amyloid
polypeptide (IAPP); and undetectable levels of somatostatin
(Sst) and pancreatic polypeptide (Ppy) (Fig. 4A). The
intracellular distribution of these proteins, as determined
by immunofluorescence, was similar to that found in primary
β cells, e.g., cytosolic localization of insulin and C-peptide
(Fig. 4B), plasma membrane-bound Glut-2 (Fig. 4C), and
cytosolic glucokinase (Fig. 4D). ERoSHK-4 (Fig. 4E) also
expressed transcription factors typical of β cells, including
Pdx1, Beta2/Neurod1, Nkx2-2, Nkx6-1, Isl-1, Pax6, and
Foxa2 (previously known as HNF3β) (Habener et al., 2005).
Like adult β cells, ERoSHK-4 cells also did not expresside gene expression comparison of ERoSHK-1 with its parental E-
hip. (B) Cellular content of insulin and C-peptide of the eight
dent experiments, as evaluated by RIA after 6–9 passages. (C)
ells and their mitotic activity (arrows). Immunohistochemical
ells. Bar, 25 μm. (D) Insulin and C-peptide contents of ERoSHK-4
riments at each time point.
Figure 4 ERoSHK cells express genes and proteins of primary β cells. (A) The expression of several genes of ERoSHK-4 cells (top) was
compared to that of isolated adult mouse islets (bottom), including Ins1 (proinsulin-1), Ins2 (proinsulin-2), Slc2a2 (Glut2), Gck
(glucokinase), Pcsk1 (prohormone convertase 1/3), Kcnj11 (Kir 6.2), Abcc8 (Sur-1), Iapp (islet amyloid polypeptide), Irs-2 (insulin
receptor substrate 2), Gcg (glucagon), Sst (somatostatin), and Ppy (pancreatic polypeptide). (B) Detection of cellular insulin and C-
peptide in ERoSHK-4 cells by immunofluorescent staining. Bar, 20 μm. (C, D) Immunofluorescent staining of membrane-bound Glut2
and cytosolic glucokinase (GK) in ERoSHK-4 cells. Bars, 20 μm. (E) Examination of the expression of several RNA transcripts in ERoSHK-
4 cells, including Pdx1 (pancreatic and duodenal homeobox 1), Neurog3 (neurogenin 3), Neurod1 (neurogenic differentiation 1),
Pax6 (paired gene 6), Pax4 (paired gene 4), Nkx2-2 (NK2 transcription factor related, locus 2), Nkx6-1 (NK6 transcription factor
related, locus 1), Isl1 (ISL1 transcription factor, LIM/homeodomain), Foxa2 (forkhead box A2, previously known as HNF3β), Nes
(nestin), and Hnf1a (HNF1 homeobox A).
46 G.D. Li et al.Neurog3 (Gu et al., 2002) and Pax4 (Smith et al., 1999) (Fig.
4E). Unexpectedly, the expression of Hnf1a, a critical
transcription factor for β-cell function (Boj et al., 2001),
was undetectable in ERoSHK-4 cells (Fig. 4E). The expression
of Nes and the pluripotency-associated gene Oct4 was also
not detected in these cells (Fig. 4E). We observed a similar
gene expression pattern in another independently derived
line, ERoSHK-6 (data not shown). Karyotype analysis of all
cell lines revealed an abnormal karyotype of 36–40 chromo-
somes. In our experience, we observed that the karyotypes
of mESCs and their derivative E-RoSH cell lines are inherently
unstable. The normal karyotype of E14 mESC cell stocks
could be maintained by periodic subcloning. A normal
karyotype of 20/20 metaphase nuclei having 40 chromo-
somes with no structural abnormalities as determined by SKY
analysis at P1 generally starts to drift after 10 passages. In
one experiment to test karyotype stability in mouse ESCs, we
determined by G-banding and SKY analysis that a normal
karyotype in 20/20 metaphase nuclei at P1 became 14/20 atp12 and then 9/20 at p18. Because of this inherent karyotype
instability and the extended culturing period needed to
derive E-RoSH cell lines and subsequently ERoSHK cell lines,
we were not able to derive ERoSHK lines with a normal
karyotype. Although it is formally possible that this inherent
karyotype instability resulted in chromosomal abnormalities
that fortuitously generated insulin-producing cells, this is
not likely as the chromosomal abnormalities are random and
nicotinamide treatment alone of karyotypically abnormal E-
RoSH or mESC never yielded insulin-producing cultures.
Ultrastructural analysis of the ERoSHK-1 to -8 lines
showed that most cells had the ultrastructural organization
expected for a regulated secretion of insulin and C-peptide.
Thus, numerous secretory granules containing the typical
dense core and clear peripheral halo of β-cell granules were
easily detected in the ERoSHK-4 and ERoSHK-6 cells (Figs. 5A
and 5B). Immunoelectron microscopy demonstrated the
presence of insulin and C-peptide in these granules and, to
a lesser density, in the Golgi apparatus (Figs. 5C and 5D),
Figure 5 ERoSHK cells properly biosynthesize and store insulin. Conventional and immunoelectron microscopy was performed to
localize the sites of insulin biosynthesis and storage in ERoSHK-6 cells. (A, B)Detectionof secretory granules (arrows)with a dense coreand
a peripheral, electron-lucent halo (A), and mitotic activity (B) by conventional electron microscopy. (C, D) Immunoelectron microscopy
determined that insulin (C) and C-peptide (D), revealed by electron-dense gold particles, were present within secretory granules and the
Golgi apparatus (dotted area), but not in nearby mitochondria and lysosomes. Bar, 1.5 μm in A and B and 300 nm in C and D.
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Figure 6 ERoSHK cells feature a stimulus-secretion coupling like that of primary β cells. Several steps of the stimulus-secretion
coupling of ERoSHK 4 cells were assessed. (A) The changes in membrane potential of ERoSHK-4 cells induced by 15 mM glucose, 100 μM
tolbutamide (Tolbu), 100 nM glibenclamide (Gliben), or 200 μM diazoxide (Diz) were monitored using bisoxonol, whose fluorescence
signal was expressed as a percentage of the depolarization induced by 40 mM KCl. Glucose and sulfonylureas depolarized ERoSHK-4
cells, whereas diazoxide hyperpolarized them. Time bar, 60 s. (B) The effects of glucose, sulfonylureas, and 20 μM verapamil (Verap)
on [Ca2+]i were followed using the fluorescent probe Fura-2. Glucose and sulfonylureas increased free cytosolic Ca
2+, whereas
verapamil decreased it. Time bar, 60 s. Each of the traces in (A) and (B) is representative of at least four experiments. (C) Amount of
insulin and C-peptide released from ERoSHK-4 cells in response to a 30-min stimulation by various glucose concentrations. Note the
equimolar release of the two proteins. (D) Known β-cell secretagogues, including sulfonylurea, KCl, L-leucine (Leu; 10 mM); forskolin
(Fors), and 3-isobutyl-1-methylxanthine (IBM), stimulated or potentiated insulin release from ERoSHK-4 cells, whereas several
inhibitors, including verapamil (Verap), diazoxide (DIZ), epinephrine (Epin), and somatostatin (SS), decreased it. ⁎Pb0.01 vs 2.8 mM
glucose; #Pb0.01 vs 8.4 mM glucose. Values in (C) and (D) are means±SEM of four to six experiments.
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49ESC-derived insulin-producing cell linesindicating a proper biosynthetic processing of the proinsulin
and its conversion into insulin. Mitosis of these insulin-
containing cells was readily observed (Fig. 5B).
ERoSHK cells secrete insulin like primary β cells
The coupling of insulin secretion to glucose level is a
fundamental physiological function of pancreatic β cells.
Therefore, glucose sensing and insulin secretion in pancrea-
tic β cells are highly coordinated processes. Glucose is first
taken up by β cells through the Glut2 transporter and then
phosphorylated by glucokinase before being metabolized by
glycolysis and mitochondrial oxidative phosphorylation to
generate ATP from ADP. The resulting increase in the
cytosolic ATP/ADP ratio then triggers the closure of KATP
channels, leading to the depolarization of the cell mem-
brane, which in turns leads to the opening of the voltage-
gated Ca2+ channels. Consequently, the intracellular free
Ca2+ level ([Ca2+]i) increases and causes exocytosis of insulin-
containing granules (Gembal et al., 1992; Newgard and
McGarry, 1995; Lang, 1999). The integrity of this molecular
sequence was assessed under stimulation by either glucose or
sulfonylureas in ERoSHK-4 and EroSHK-6 cells, but data only
for ERoSHK-4 are presented here. We found that 15 mMFigure 7 Transplantation of ERoSHK cells corrects the hyperglycem
two injections of streptozotocin (STZ; solid arrows) to induce hypergl
were either transplanted subcutaneously (open arrow) with 5×10
operated (open circles, n=5). Blood glucose level was monitored e
surgically removed upon restoration of normoglycemia (⁎). The
pretransplantation levels (solid triangles, n=4). (B) Immunostaining o
of control mice (left), but not in those of the hyperglycemic mice th
cells (right). In the latter two types of mice, islets still contained glu
controls (Cont), serum insulin levels were much decreased (Pb0.01)
from which the ERoSHK cell graft was removed (Rmv). In contrast, the
streptozotocin-injected mice that showed normal blood glucose leve
(n=4). (D) Histological analysis of an ERoSHK-4 cell graft revealed
immunostaining of many cells (middle), but lack of glucagon immunglucose, 100 μM tolbutamide, or 100 nM glibenclamide depo-
larized ERoSHK-4 cells (Fig. 6A) by a mechanism blocked by
diazoxide, a drug that opens KATP channels, as observed in
primary β cells. These same secretagogues also increased
[Ca2+]i in ERoSHK-4 (Fig. 6B) by a mechanism that, as in
primary β cells, was abrogated by verapamil, a blocker of
L-type Ca2+ channels. Increasing the glucose concentration
from 2.8 mM to postprandial glucose concentrations (5.6 or
8.4 mM) significantly increased the equimolar release of
both insulin and C-peptide (Fig. 6C). Insulin release from
ERoSHK-4 cells were also stimulated by a variety of other
nutrient and nonnutrient β-cell secretagogues and poten-
tiators, including tolbutamide, glibenclamide, L-leucine,
high potassium, forskolin, and isobutylmethylxanthine, and
were inhibited by diazoxide, verapamil, epinephrine, and
somatostatin (Fig. 6D), which also suppress glucose-induced
insulin secretion in primary β cells. However, ERoSHK-4
cells differed from primary β cells in having a high basal
insulin secretion rate, equivalent to ∼2.5% of insulin
content in the presence of nonstimulatory 2.8 mM glucose
(Fig. 6D), and in reaching maximal insulin secretion at
8.4 mM (Fig. 6C). These observations demonstrate that
ERoSHK cells retained many functional features of primary
β cells, notably the ability to recognize glucose as aia of streptozotocin-treated SCID mice. (A) SCID mice received
ycemia. When blood glucose level exceeded 350 mg/dl, the mice
6 ERoSHK-4 cells (closed circles and triangles, n=10) or sham
very 4–5 days. The cell grafts of some transplanted mice were
high blood glucose levels in these mice rapidly returned to
f pancreas for insulin (top) revealed abundant β cells in the islets
at were sham-operated (middle) or transplanted with ERoSHK-4
cagon-producing α cells (bottom). Bar, 25 μm. (C) Compared to
in hyperglycemic mice that had not been transplanted (Hyg) or
se levels were significantly (Pb0.01) higher than control levels in
ls as a result of an ERoSHK cell graft (Tx). Values are means±SEM
mitotic cells (inset) in the H&E-stained section (left), insulin
ostaining (right). Bar, 25 μm.
50 G.D. Li et al.stimulus of insulin secretion and to release the hormone
through a KATP- and Ca2+-regulated pathway.
ERoSHK cell transplantation reverses hyperglycemia
in streptozotocin-treated mice
To determine if the in vitro insulin release of ERoSHK cells
could be retained in vivo, 5×106 ERoSHK-4 (Fig. 7A) or
ERoSHK-6 cells (data not shown) were transplanted sub-
cutaneously in the front axilla of SCID mice made hypergly-
cemic (blood glucose level N350 mg/dl) after two injections
of 125 mg/kg streptozotocin. These high blood glucose levels
were progressively reduced in all cell-transplanted, but not
sham-transplanted, mice, to reach normoglycemia within
2 weeks (Fig. 7A), despite the virtual absence of insulin-
containing β cells in the native pancreatic islets of the
animals (Fig. 7B). Removal of the cell grafts rapidly increased
blood glucose levels to pretransplant levels (Fig. 7A). The
corresponding serum insulin levels, which were barely
detectable in the streptozotocin-treated mice, increased
significantly in excess of the prediabetic level after cell
transplantation and then returned to pretransplant levels on
removal of cell grafts (Fig. 7C). These observations show that
the correction of hyperglycemia was mediated by the insulin
secreted from the transplanted cells. In addition, histology
revealed that the graft had organized into an organoid
architectural pattern of nodules consisting of cells with the
cytological features of the pregrafted cells (Fig. 7D). The
return to normoglycemia in the cell-transplanted animals
was followed by a period of sustained hypoglycemia that
stabilized at 40–50 mg/dl (Fig. 7A), allowing for the moni-
toring of the animals for up to 3 months. During this period,
and despite continuous mitotic activity (Fig. 7D), teratoma
formation was never observed in the immunocompromised
mice transplanted with ERoSHK-4, ERoSHK-6, or their
parental E-RoSH cells. Although we observed mitotic activity
in the grafted cells and an increase in graft size, subcuta-
neously transplanted ERoSHK cells, unlike transplanted ESCs,
never grew to a visible tumor. In the same period (16 days) in
which 106 ESCs developed into a teratoma of 1 cm in
diameter, 5×106 ERoSHK cell grafts remained impalpable. It
took 50 and 75 days for these grafts to reach diameters of 2–3
and 3–3.5 mm, respectively. After removal, the grafted cells
could be propagated in culture without significant loss of
cellular phenotype or functions. Therefore, we cannot
conclude categorically from these transplantation studies
whether insulin-producing ERoSHK cells are tumorigenic.
The ERoSHK cell-transplanted, but not the sham-
operated, animals also regained a normal rate of body weight
gain, indicating proper sensitivity to the newly secreted
insulin by ERoSHK cells.
Discussion
In this report, we describe the first generation, isolation, and
propagation of clones of mESC-derived insulin-producing cell
lines, through the differentiation of lineage-restricted E-
RoSH cell lines (Lian et al., 2006). Such approach is
strategically different from many of the previously described
protocols for differentiating ESCs into pancreatic β cells
(Assady et al., 2001; Lumelsky et al., 2001; Leon-Quintoet al., 2004; Fujikawa et al., 2005; Shi et al., 2005; D’Amour
et al., 2006; Schroeder et al., 2006a).
First, instead of enhancing the differentiation of mESCs
into EBs enriched for heterogeneous cell types that
collectively expressed a high level of mesoendodermal
markers, our multistage strategy is unique in the isolation
of lineage-restricted clonal stem cell lines that are devel-
opmentally intermediate between ESCs and insulin-produ-
cing cells. These cell lines, the E-RoSH cell lines, were
isolated from CD9hi, SSEA-1neg cells in EBs and express
mesodermal and definitive endoderm markers that are at
least 10× higher than those in ESCs (Lian et al., 2006).
Therefore, derivation of insulin-producing cells was
initiated using a homogeneous cell population that was
poised for endodermal differentiation, and this greatly
improved the efficiency of generating insulin-producing
cells.
Second, the use of a lineage-restricted cell line simplified
the protocol for generating insulin-producing cells. We have
previously reported that serum deprivation or general
starvation induces differentiation of E-RoSH or RoSH cells
(Que et al., 2007) and increases expression of mesoderm-
and endoderm-associated genes (Fig. 1C) in the absence of
exogenously added growth factors, small molecules, or
antibodies such as FGF2, activin, TGFβ, retinoic acid, and
anti-Shh antibodies. These critical factors are presumably
provided in the endothelial signals from the vascular
structures that were formed at the initiation of differentia-
tion in the E-RoSH cells (Zaret, 2002; Nikolova et al., 2006;
Jacquemin et al., 2006) (Fig. 2A). These signals were
apparently not sufficient to induce insulin production in
the cells. Exogenous addition of nicotinamide was essential
in inducing terminal differentiation into insulin-producing
cells. Nicotinamide is routinely used in the differentiation of
progenitor cells into insulin-producing cells (Schroeder et
al., 2006b) as it is thought to induce replication (Sandler et
al., 1989) and/or differentiation (Otonkoski et al., 1993) of
pancreatic β cells while protecting pancreatic β cells (Eizirik
et al., 1993). In our experiments, nicotinamide induced
within days production of sizable levels of insulin and C-
peptide in the cultures from which we then independently
established several clonal ERoSHK cell lines. Incidentally,
nicotinamide has little effect on the growth or insulin
production of undifferentiated E-RoSH cells (unpublished
observations). While the insulin levels were significantly
lower than those in primary β cells by up to one-fifth, they
compare favorably with those of the available cell lines that
are extensively used in β-cell research (Poitout et al., 1996).
Ultrastructural analysis showed that, like primary β cells,
dense core and single membrane-bound secretory granules
were the major storage sites of insulin in ERoSHK cells and
that these differentiated insulin-producing cells were still
capable of active mitosis.
Third, the use of lineage-restricted E-RoSH cells also
resulted in a much reduced repertoire of cell types
generated. This, coupled with massive cell death possibly
through starvation, inhibition of proliferation leading to
apoptosis, or natural attrition of terminally differentiated
cells, facilitated isolation of putative insulin-producing cells
by limiting dilution. In addition, this protocol was also highly
reproducible. We have applied this protocol to RoSH cell lines
that are highly similar to E-RoSH cell lines but are derived
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Lian et al., 2006), and generated similar insulin-producing
RoSHK cell lines (Li et al., 2009).
Fourth, unlike the current state of the art in pancreatic
differentiation of ESCs, in which only heterogeneous,
transient, insulin-producing cultures are produced, we
established scalable insulin-producing cell lines. These
cell lines are amenable to subcloning from single cells,
can be stably propagated and expanded, and can withstand
repeated cycles of freeze–thaw without loss of cell
morphology or insulin production. Therefore, these lines
could resolve the present difficulty in large-scale prepara-
tion of homogeneous insulin-producing cell populations for
evaluation of their physiological and pharmacological
properties and reversal of hyperglycemia in diabetic mice
with a homogeneous population of cells that do not form
teratomas.
The propagation of ERoSHK cells in long-term culture
without viral and chemical transformation and their functional
properties suggest a fetal- or neonatal- rather than an adult-
like phenotype of the pancreatic isletβ cells. Fetal or neonatal
pancreatic islet β cells, unlike the generally quiescent adult
pancreatic islet β cells, are actively replicating, with a high
basal insulin secretion and a poor coupling of glucose
concentration change to induction of insulin secretion, e.g.,
pancreatic islet β cells from d20 rats secrete the same amount
of insulin when exposed to 15.6 or 5.6 mM glucose (Aguayo-
Mazzucato et al., 2006). After birth, neonatal pancreatic islet
cells rapidly acquire the adult phenotype through a still poorly
defined postnatal maturation process (Milner et al., 1972;
Phelps et al., 1978; Grill et al., 1981). In this regard, the
continued proliferation of ERoSHK cells with their poor
coupling of glucose stimulus–insulin secretion and elevated
basal insulin secretion (Figs. 6C and 6D) suggests an immature
phenotype rather than the mature phenotype of adult
pancreatic islet β cells. The hypoglycemia (Fig. 7A) and
hyperinsulinemia (Fig. 7C) observed in diabetic mice trans-
planted with ERoSHK cells are also consistent with the
transplantation of immature insulin-producing cells that
have poor coupling of glucose stimulus–insulin secretion. It
was previously noted that d20 neonatal rats are hyperglycemic
and hyperinsulinemic, and the former has been attributed to
peripheral insulin resistance while the latter to high basal
secretion of insulin (Aguayo-Mazzucato et al., 2006). There-
fore, transplantation of immature cells with high basal insulin
secretion and poor coupling of glucose–insulin secretion into
adult diabetic mice with no peripheral insulin resistance will
result in hyperinsulinemia and hypoglycemia. However, the
continued proliferation of ERoSHK cells after transplantation
and their abnormal karyotype suggest that the hyperinsuline-
mia and hypoglycemia could be indicative of an insulinoma
phenotype. Although we cannot rule out this possibility, the
characteristics of our cells are significantly different from
those of insulinoma cells as reported in the literature (Li et al.,
2009). For instance, transplanted insulinoma cells are known
to induce hyperinsulinemia and hypoglycemia through the
formation of a large cell mass that collectively secretes large
amounts of insulin. In normal rats, subcutaneous injection of
1×106 INS-1 insulinoma cells induced a state of hyperinsuline-
mia and hypoglycemia that began slowly at week 2. From the
third week, the blood glucose decreased linearly and
exponentially to less than 30 mg/dl and this decreaseparalleled the growth rate of the cell grafts that generally
form large 1-cm tumors by week 5 (Vozzi et al., 1997). In sharp
contrast, blood glucose level in diabetic mice transplanted
with ERoSHK cells fell exponentially from hyperglycemia
(∼450 mg/dl) to normoglycemia (∼100 mg/dl) within the
first 3 weeks and thereafter very gradually over 3 weeks to
stabilize at a hypoglycemic state of ∼50 mg/dl (Fig. 7A). The
average size of ERoSHK cell grafts at week 10 is ∼0.35 cm.
Together, these observations suggest that the insulin-
producing cell lines generated from differentiation of ESC
through the lineage-restricted E-RoSH cells are more likely
to be immature with some resemblance to fetal- or
neonatal-like pancreatic islet β cells and could potentially
be induced to mature into adult pancreatic islet β cells
through the still poorly understood process of postnatal
maturation.
In conclusion, we have described a strategy to reprodu-
cibly generate large, homogeneous insulin-producing cell
populations with negligible or no risk of teratoma formation
frommESCs. This derivation will provide a strategic approach
for establishing insulin-producing cell lines from human ESCs
inasmuch as the similarities and differences between mouse
and human ESCs permit. Additionally, it also highlights a
potential but hitherto understated problem of generating
immature and not mature adult pancreatic islet β cells when
differentiating ESCs in vitro.
Materials and Methods
Derivation of insulin-producing cell lines
E-RoSH cells were maintained as previously described (Lian
et al., 2006). ERoSHK cell lines were derived by serum
starving 4×108 E-RoSH cells for 72 h in INS medium without
serum (RPMI 1640 medium containing 1 mM sodium pyruvate,
50 μM 2-mercarpetoethanol, 10 mM Hepes, pH 7.4), then
culturing in INS medium with 2% FCS and 10 mM nicotinamide
for 48 h, and finally culturing in INS medium with 10% FCS for
48 h. The sequence of serum starvation followed by
nicotinamide treatment was repeated on average about
three to four times until ∼1000 cells were left. The surviving
cells were then trypsinized and replated in limiting dilution
onto 96-well plates. The cells were maintained in INS
medium with 10% FCS. Each individual well was monitored
for the presence of epithelial-like cells. Wells with cells
resembling E-RoSH cells were discarded. For derivation of
the ERoSHK-1 and -2 lines, an additional exposure to 5 μM
gleevec (Biaffin GmbH, Germany) in INS medium with 2% FCS
for 72 h was included after the nicotinamide treatment. To
assess E-RoSH cell viability during the gleevec treatment,
samples of 1×106 E-RoSH cells were removed at 0, 24, 48,
and 72 h; labeled for 15 min at 37 °C with 1 ml 10 μM CFDA
(Molecular Probes, Eugene, OR, USA) and 10 μg/ml propidium
iodide in PBS; incubated in the presence of 1 mg/ml RNase A
for 30 min at room temperature; fixed in 4% formaldehyde;
and analyzed by flow cytometry.
Determination of insulin and C-peptide
After being washed, the cultures were extracted in acid–
ethanol and total cellular insulin and C-peptide contents
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(Millipore), as previously reported (Li et al., 2000; Li et al.,
2004). For secretion experiments, cells were seeded into
24-well culture plates for 2–3 days. The cells were then
washed and preincubated for 30 min in Krebs–Ringer–
bicarbonate–Hepes buffer (KRBH) containing 2.8 mM glu-
cose (Li et al., 2004). Afterward, the solution was removed
and cells were incubated in KRBH containing test reagents
for another 30 min. The supernatants were removed for
determination of insulin and C-peptide secretion. The
attached cells were also extracted in acid–ethanol for
measurement of total cellular content of insulin and C-
peptide. The secretion rate was expressed as a percentage
of content, to correct for differences in cell numbers
among the wells.
Analysis of gene expression
E14 mESC and ERoSH2.1 cells were induced to differentiate
by culturing single cells in suspension at a density of 105
cells per 6-cm plate. After 48 h, ESCs formed tightly packed
embryoid bodies that were analogous to developing
embryos (Risau et al., 1988) and, in contrast, E-RoSH
cells formed hollow bodies that were observed when either
E-RoSH or RoSH2 cells were induced to undergo Matrigel-
induced endothelial differentiation (unpublished data; Yin
et al., 2004; Lian et al., 2006). At 2, 3, 4, and 7 days,
aliquots of cells were harvested for RNA analysis. Total RNA
was extracted from the cells with Trizol reagent (Invitro-
gen) and purified over a spin column (Nucleospin RNA II
System; Macherey–Nagel GmbH, Düren, Germany) accord-
ing to the manufacturers’ protocol. The expression of
transcription factors in mouse ES and E-RoSH cells was
compared by quantitative RT-PCR, using a TaqMan low-
density array (Applied Biosystems, Foster City, CA, USA).
Total RNA (1 μg) was converted to cDNA with random
primers in a 50-μl reaction volume, using a High Capacity
cDNA Archive Kit (Applied Biosystems). The cDNA was
diluted with distilled water to a volume of 100 μl. Primer
sets (1 μl) for the TaqMan low-density array were used
according to the manufacturer’s instructions (Applied
Biosystems). For RT-PCR using the SuperArray system,
reverse transcription of RNA samples was also performed
as described below. The cDNA solution (1 μl) was used for
each primer set in the PCR arrays (SuperArray, Frederick,
MD, USA), according to the manufacturer’s protocol. Global
gene expression levels in ERoSHK cells and parental
ERoSH2.1 cells were measured by microarray analysis,
using the Sentrix MouseRef-8 Expression BeadChip (Illu-
mina, San Diego, CA, USA). Total RNA (2 μg) from two
biological replicates of cells was converted to biotinylated
cRNA, using the Illumina RNA Amplification Kit (Ambion,
Austin, TX, USA) according to the manufacturer’s direc-
tions. Samples were purified using the RNeasy Kit (Qiagen,
Valencia, CA, USA). Hybridization to the Sentrix MouseRef-8
Expression BeadChip holding ∼24,000 unique gene probes
(Illumina), washing, and scanning were performed accord-
ing to the Illumina BeadStation 500x manual. The data were
normalized and analyzed using Illumina BeadStudio pro-
vided by the manufacturer. Transcript signals that were
below the limit of detection at 99% confidence were not
further considered.RT-PCR
Islets of Langerhans were isolated from the pancreas of adult
C57BL/6J mice by perfusing collagenase through the main
pancreatic duct and then separating the disaggregated
pancreatic islets on Ficoll gradient centrifugation as
described (Wollheim et al., 1990). Total RNA of ERoSHK
cells and control pancreatic islets was extracted and purified
using the RNeasy Mini Kit 250 (Qiagen) and quantified by UV
absorbance. The purified RNA (250 ng per sample) was
converted into cDNA by M-MLV reverse transcriptase (Pro-
mega) and amplified by PCR in a Thermocycler (Biometra),
using Taq DNA polymerase (Promega). The conditions of the
PCR were an initial denaturation at 94 °C for 5 min followed
by 35 cycles of denaturation at 94 °C for 30 s, annealing of
primers to target DNA fragments at 55–65 °C for 45 s, and
elongation of the complementary strand at 72 °C for 1 min.
To minimize RT-PCR artifacts from genomic DNA contamina-
tion, we designed intron-spanning primers whenever possible
and treated all RNA samples with 27 units DNase I (Qiagen)
during RNA purification. All PCR experiments also included
PCR amplifications of RNA samples that had not been treated
with RT. The primers and the PCR conditions for each primer
set are summarized in Table S1 of the supplementary data.
Electron microscopy
For conventional electron microscopy, monolayers of all
ERoSHK cell clones were fixed for 2 h at room temperature in
a 2.5% glutaraldehyde solution in 0.1 M phosphate buffer.
Cultures were then dehydrated and embedded in Epon in
situ, as previously reported (Vozzi et al., 1995). For
immunoelectron microscopy, pellets of ERoSHK-6 cells were
washed twice in 0.1 M phosphate buffer, before a 5-min
fixation at room temperature in 4% paraformaldehyde and
0.1% glutaraldehyde, followed by a 60-min fixation in 4%
paraformaldehyde (all fixatives were diluted in 0.1 M
phosphate buffer, pH 7.4). The cells were then frozen and
cryosectioned with an EMFCS cryo-ultramicrotome (Leica),
as previously reported (Bosco et al., 2005; Scheiermann et
al., 2007). Ultrathin sections were mounted on Parlodion-
coated copper grids, incubated as described (Bosco et al.,
2005; Scheiermann et al., 2007), and photographed in a
CM10 electron microscope (Philips, Eindhoven, The Nether-
lands). Immunolabeling for insulin was carried out for 1 h at
room temperature using either a guinea pig polyclonal serum
or mouse monoclonal antibodies, diluted 1:100. Antigen–
antibody complexes were revealed for 20 min at room
temperature using either 15-nm gold particles coated with
protein A or a goat anti-mouse IgG serum coupled to 10-nm
gold particles (British Biocell International, Cardiff, Wales)
diluted 1:10, whichever was appropriate. Immunolabeling
for C-peptide was performed according to the same protocol,
using a mouse monoclonal antibody (diluted 1:800). In all
incubations, controls included exposure of the sections to
only the protein A-coated gold particles or to the gold-
conjugated goat antibodies against either rabbit or mouse
IgG, whichever was appropriate. None of these incubations
resulted in a sizable, specific staining of the sections (data
not shown). Furthermore, mitochondria, lysosomes, and the
nonvesicular regions of cytosol were not labeled by the
combination of the first and cognate secondary antibodies.
53ESC-derived insulin-producing cell linesMeasurement of membrane potential and [Ca2+]i
Membrane potential was measured by incubating 2×106 cells
in 100 nM bisoxonol and then monitoring fluorescence using a
spectrofluorometer (Perkin–Elmer LS-50B) at excitation and
emission wavelengths of 540 and 580 nm, respectively.
Bisoxonol signals were expressed as a percentage of those
observed in the presence of 40 mM K+, which induced a
maximal depolarization (Li et al., 2000; Li et al., 2004). [Ca2+]i
was determined using the fluorescent probe Fura-2 (Li et al.,
2000; Li et al., 2004).
Immunofluorescence staining
ERoSHK cells cultured on coverslips for 3–4 days were washed
twice in PBS (pH 7.4) and fixed for 10 min at room
temperature in 3.7% paraformaldehyde in PBS. Following
two washes in PBS, the cells were permeabilized by a 10-min
incubation in PBS containing 0.2% saponin (Sigma). After a
30-min blockade in PBS containing 20% normal serum (from
goat, swine, or rabbit, whichever was relevant), the cover-
slips were incubated for 1.5 h at room temperature with an
antibody against the target protein (insulin, mouse C-
peptide, glucokinase, Glut2) in PBS supplemented with 1%
BSA. After two washes, the coverslips were incubated with
an appropriate FITC- or TRITC-conjugated second antibody
for 45 min. Thereafter, coverslips were washed and mounted
on glass slides with FluorSave reagent (CalBiochem). Samples
were examined by laser confocal microscopy (Olympus IX 70
Fluoroview 300).
Animal experiments
All animal experimental procedures were approved by the
institutional IACUC. Six- to eight-week-old SCID mice were
given two ip doses of 125 mg/kg body wt freshly prepared
streptozotocin (Sigma), in 100 mM sodium citrate buffer, pH
4.5, 2–3 days apart. When blood glucose exceeded 350 mg/
dl, 5×106 ERoSHK-4 or ERoSHK-6 cells were implanted
subcutaneously in a front leg. For some transplanted mice,
the cell grafts were surgically removed 7–8 weeks after
transplantation, and the mice continued to be monitored for
a few more weeks. Blood glucose, body weight, and serum
insulin levels were monitored before and after cell trans-
plantation or after removal of the grafts. About 3 months
after cell transplantation, the mice were sacrificed, and the
cell grafts and the pancreas were taken for histological
examination.
Histology
Tissue samples and cytospun preparation of cells were fixed
in 10% formalin for 24–48 h, dehydrated, embedded in
paraffin, sectioned, and processed for either conventional
hematoxylin–eosin staining or immunohistochemistry (IHC).
For IHC, primary antibodies (Dako, Carpinteria, CA, USA)
included a guinea pig serum against insulin and a rabbit
serum against glucagon. Biotinylated secondary antibodies
and the ABC–enzyme complexes were purchased from Vector
Laboratories (Burlingame, CA, USA). Slides were examined
under light microscopy.Statistical analysis
The results were expressed as means±SEM and were
analyzed by t test. A difference was considered significant
when Pb0.05.
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